Zhitong Finance App News, Baokang Shiyun-B (02592.HK) announced that on December 10, 2025, the company's wholly-owned subsidiary Cloudbreak USA successfully held a Phase 2 post-clinical trial meeting with the US Food and Drug Administration. The conference involved the clinical development of CBT-004, which is a potential first-in-class preservative-free eye drop suitable for treating vascularized eyelid fissures. This condition is common in people with excessive UV exposure and the elderly.

Zhitong Finance App News, Baokang Shiyun-B (02592.HK) announced that on December 10, 2025, the company's wholly-owned subsidiary Cloudbreak USA successfully held a Phase 2 post-clinical trial meeting with the US Food and Drug Administration. The conference involved the clinical development of CBT-004, which is a potential first-in-class preservative-free eye drop suitable for treating vascularized eyelid fissures. This condition is common in people with excessive UV exposure and the elderly.